Abstract:OBJECTIVE Unlike its pediatric counterpart, adult diffuse intrinsic pontine glioma (DIPG) remains largely unelucidated. In this study, the authors examined the clinical, radiological, pathological, molecular, and clinical aspects of 96 adult DIPGs. METHODS The National Brain Tumor Registry of China (April 2013–December 2019) was used to collect data on radiologically diagnosed adult DIPG patients. Survival analysis was conducted using Kaplan-Meier curves and univariate and multivariate Cox regression. The chi-square test/Wilcoxon rank-sum test and multivariable logistic regression were used to examine the clinical and radiological characteristics of patients with long-term survival (LTS). Interaction analyses between clinical factors were also conducted. RESULTS The median age at symptom onset was 33.5 years, and the median duration of symptoms was 4.5 months. The frequencies of H3K27M and IDH1 mutations were 37.2% and 26.5%, respectively. All adult DIPG patients had a median overall survival (OS) of 19.5 months, with 1-, 2-, and 3-year survival rates of 67.0%, 42.8%, and 36.0%, respectively. The median OS of 40 patients who did not undergo treatment was 13.4 months. Patients with H3K27M-mutant tumors had a poorer prognosis than those with IDH -mutant tumors (p < 0.001) and H3K27M(−)/ IDH –wild-type tumors (p = 0.002), with a median OS of 11.4 months. The median OSs of patients with H3K27M-mutant tumors who received treatment and those who did not were 13.8 months and 7.5 months, respectively (p = 0.016). Among patients with and without a pathological diagnosis, H3K27M mutation (p < 0.001) and contrast enhancement on MRI (p = 0.003), respectively, imparted a worse prognosis. Treatments were the predictive factor for patients with H3K27M-mutant tumors (p = 0.038), whereas contrast enhancement on MRI was the prognostic factor for the H3K27M(−) group (p = 0.038). In addition, H3K27M mutation and treatment were significant predictors for patients with symptom duration ≤ 4 months (H3K27M, p = 0.020; treatment, p = 0.014) and tumors with no contrast enhancement (H3K27M, p = 0.003; treatment, p = 0.042). Patients with LTS were less likely to have cranial nerve palsy (p = 0.002) and contrast enhancement on MRI at diagnosis (p = 0.022). CONCLUSIONS It is recommended that all adult DIPG patients undergo genomic testing for H3K27M and IDH mutations. Despite the low prevalence, additional study is needed to better characterize the efficacy of various treatment modalities in adults with DIPG.

Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma

Current immunotherapeutic approaches to diffuse intrinsic pontine glioma

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy

Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies

Diffuse Intrinsic Pontine Glioma (DIPG): A Review of Current and Emerging Treatment Strategies.

Basic and Clinical Research Progress of Diffuse Intrinsic Pontine Glioma

Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma

Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma

Immunotherapy for Malignant Glioma: Current Status and Future Directions

Csig-12. glioma microenvironment: functions, molecular mechanisms, and therapeutic implications

Research Progress in Immunotherapy of Gliomas

Immunosuppressive Microenvironment in H3K27 Mutant Pediatric Diffuse Midline Glioma: Single-Cell and Bioinformatics Insights on CD8A, IL7R, and ICAM1

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes

Emerging Therapeutic Strategies for Diffuse Intrinsic Pontine Glioma: A Systematic Review

Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma

Diffuse Intrinsic Pontine Gliomas Exhibit Cell Biological and Molecular Signatures of Fetal Hindbrain-Derived Neural Progenitor Cells

Clinical Presentation, MRI findings and Molecular insights in Diffuse Intrinsic Pontine Gliomas (DIPGs): A Comprehensive Review.

Clinical trials for diffuse intrinsic pontine glioma: the current state of affairs

DIPG-66. MULTIPLEXED IMMUNOFLUORESCENCE MAPPING AND AI MODEL PREDICTION OF TUMOR MICROENVIRONMENT IN DIFFUSE MIDLINE GLIOMAS

Radiotherapy for Diffuse Intrinsic Pontine Glioma: Insufficient but Indispensable

Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients